Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
Johns Hopkins University
Study ID
NCT00363168
Phase
PHASE1
Status
Completed

Conditions

  • Choroidal Neovascularization

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This research is being done to look at the effects of an experimental drug, ranibizumab, on a condition called "predominantly hemorrhagic subfoveal choroidal neovascularization (CNV)" due to wet age-related macular degeneration. A predominantly hemorrhagic CNV lesion is diagnosed when at least 50% of the choroidal neovascular lesion is occupied by blood under the retina. We want to find out if injections of ranibizumab into the eye will help patients with this condition.

Key Dates

First listed
Aug 15, 2006
Start date
Aug 31, 2006
Status verified
Sep 2012
Primary completion
Jun 30, 2008
Completion
May 31, 2009

Study Design

Enrollment
7 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: A
    0.3 mg/0.05 ml dose of ranibizumab
  • Experimental: B
    0.5 mg/0.05 ml dose of ranibizumab

Primary Outcome Measure

Number of Subjects Avoiding 15 or More Letter Loss of Best Corrected Visual Acuity From Baseline to 12 Months on an Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity Chart Measured at 4 Meters. [ Time Frame: 12 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
The Wilmer Eye Institute at Johns HopkinsBaltimoreMaryland21287-

Find similar trials in Baltimore, MD

By research site
The Wilmer Eye Institute at Johns Hopkins· Baltimore, MD

Related Studies